Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 2c

Note: EPS may not be comparable

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.56), $0.02 worse than the analyst estimate of ($0.54).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
• Navan, Inc. (NAVN) Tops Q2 EPS by 1c, Offers Guidance